British Woman Is The First Patient To Test Natural Cancer Cure Vaccine
Year after year, we get a lot of developments that could help us cure the BIG C or also known as Cancer. And looks like, we are closer to find the solution for this deadly disease. A British woman has become the world’s first patient to try out the first ever natural cancer cure administered via a vaccine. This new vaccine has been designed to activate the body’s own immune system so that it destroys tumors that have already spread in the body.
The 35-year-old woman named Kelly Potter will have the trial of the vaccine over the course of two years in an attempt to eradicate the cervical cancer she was diagnosed with in July 2015. Patients on the trial will also be prescribed a chemotherapy drug that would at low doses, “lift the brakes” on the immune system. When that happens, it is no longer prevented from attacking the body’s own cancer cells. Kelly lives in Beckenham, Kent when she was diagnosed with stage four cervical cancer and was eligible for the trial at Guy’s Hospital in London because the disease has unfortunately spread to other sites in her body.
“Although I had excellent treatment at Guy’s where the cancer was stabilised, it had already spread to spots on my liver and lungs. So when I was told that I may be eligible for this trial, I was delighted, To be part of this trial has changed my life for the better. It’s been a very positive experience and really interesting. I feel honoured to be involved. You get the best treatment anyway at Guy’s but it’s fantastic to be part of something that could be ground breaking,” - Kelly Potter
Kelly was injected with the vaccine on February 9, 2015 and she still has another seven visits to the hospital to complete the trial and treatment. Doctors have already warned her that she may experience flu-like symptoms but none has manifested on her body.
“My hope for the future is to beat the cancer for as long as I can, and if I can’t, I have come to terms with that. I would like to go on and inspire others with cancer,” - Kelly Potter
“We know that the immune system in patients with advanced cancer is suppressed, so it’s unable to recognise and kill cancer cells, In this trial we are investigating a form of immunotherapy designed to activate the body’s immune system by administration of a vaccine based on fragments to a key cancer protein,” - Professor Hardev Pandah, principal investigator on the trial from the University of Surrey in Guildford.
“The unique feature of this study is the use of additional agents to boost the vaccination response. It is hoped this will abolish the inhibitory effect of regulatory immune cells present in the patients’ circulation, which are believed to have limited the effectiveness of previous cancer vaccine approaches,” - James Spicer
The vaccine is containing a small fragment of protein from an enzyme called human telomerase reverse transcriptase (hTERT), this enzyme allows cancer cells to divide continuously. It is hoped that by injecting this antigen into the bloodstream, it will stimulate the immune system to make antibodies that attack cancer cells but leave normal, healthy cell untouched.